Detalles de la búsqueda
1.
Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent ß-thalassemia/Hb E patients.
Ann Hematol;
100(4): 891-901, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33388858
2.
Exploring health-related quality of life among non-Hodgkin's lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand.
Support Care Cancer;
29(11): 6511-6522, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33909148
3.
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
BMC Cancer;
19(1): 184, 2019 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30819138
4.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Lancet Oncol;
19(11): 1449-1458, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30348538
5.
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
Br J Haematol;
183(3): 400-410, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30168134
6.
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
N Engl J Med;
372(10): 944-53, 2015 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25738670
7.
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
Blood;
127(6): 713-21, 2016 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-26631116
8.
High proportion of TAFRO syndrome in Thai adult Castleman's disease patients: a 10-year experience.
Ann Hematol;
97(6): 1019-1026, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29464312
9.
A prospective analysis for prevalence of complications in Thai nontransfusion-dependent Hb E/ß-thalassemia and α-thalassemia (Hb H disease).
Am J Hematol;
93(5): 623-629, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29359464
10.
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
Br J Haematol;
179(1): 66-74, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28653400
11.
Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: A multicenter study based on real-world data.
Blood Cells Mol Dis;
66: 24-30, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28806577
12.
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study.
Haematologica;
102(5): 895-902, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183846
13.
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.
Am J Hematol;
97(8): E281-E284, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35560253
14.
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Blood Cells Mol Dis;
57: 23-9, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26852651
15.
Anemia and Neutropenia in Copper-Deficient Patients: A Report of Two Cases and Literature Review.
J Med Assoc Thai;
99(6): 732-6, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29901325
16.
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.
Br J Haematol;
168(2): 284-90, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25212456
17.
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.
Blood;
131(2): 263-265, 2018 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29097381
18.
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Lancet Oncol;
15(3): 343-52, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24521993
19.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol;
15(11): 1195-206, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25242045
20.
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
Blood;
120(5): 970-7, 2012 Aug 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-22589472